In detail, in diabetic patients with previous cardiovascular events without HF, metformin is considered the first-choice drug, as well as the analogues of GLP1 and SGLT2 inhibitors, while in patients with HF, the first-line drugs are now the inhibitors of SGLT2, while metformin and the GLP1 receptor agonists are the second-line drugs [18]. Here, GLP1R is linked to hydrops fetalis.